Blog Immune Response Virus 
NIH Director's Blog: Drug Development
JUNE 30, 2020
A major one is: just how well do those particular antibodies neutralize the virus to fight off the infection and help someone recover from COVID-19? Fortunately, most people get better—but should the typical antibody response take the credit? Not surprisingly, all volunteers had produced antibodies in response to the virus.
Codon
SEPTEMBER 29, 2024
On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. Dozens of diverse chemical markers and de novo , evolutionary distinct proteins littered the virus' surface, indicating a previously unseen biological logic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NIH Director's Blog: Drug Development
MARCH 18, 2021
Yet they are the source for many of the viruses that have spilled over into humans with devastating effect, including rabies, Ebola virus, Nipah and Hendra viruses, severe acute respiratory syndrome coronavirus (SARS-CoV), and, likely, SARS-CoV-2. Despite carrying all of these viruses, bats rarely show symptoms of being sick.
Alta Sciences
JANUARY 11, 2024
The in vivo nonclinical study of cell and gene therapies includes a thorough understanding of on-and-off-target activity, immune responses, and other adverse events just to name a few. There are three primary vectors employed in gene therapy: adeno-associated virus (AAV), adenovirus, or lentivirus vectors.
NIH Director's Blog: Drug Development
FEBRUARY 1, 2022
The ACE2 drug candidate, which is soluble and degrades in the body, also proved ineffective in neutralizing the virus. In the lab, it also appeared to neutralize the virus as well as monoclonal antibodies used to treat COVID-19. In fact, the decoy bound just as well, if not better, to new variants compared to the original virus.
PerkinElmer
JANUARY 25, 2023
Confronting and containing the spread of other infectious diseases like tuberculosis, influenza A and B as well as respiratory syncytial virus (RSV) also remained top global health priorities, as was testing to prevent the transmission of sexually transmitted infections, tickborne diseases and more. With the expanding territory of I.
NIH Director's Blog: Drug Development
OCTOBER 27, 2020
Another promising strategy is drugs that target the proteins within human cells that the virus needs to infect, multiply, and spread. These studies narrowed the list to 73 human proteins that the virus depends on to replicate. That’s the strategy employed by remdesivir , the only antiviral drug currently authorized by the U.S.
Expert insights. Personalized for you.
52 
Let's personalize your content